A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

NCT Number	NCT07425821
Lead Sponsor	International AIDS Vaccine Initiative Collaborators: Biomedical Advanced Research and Development Authority
Conditions	Marburg Virus Disease
Enrollment	112 participants
Start Date	2026-03-27
Primary Completion	2027-11 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-15